News Headlines Article

FDA OKs immunotherapy drugs for bladder, blood cancers
Modern Healthcare

U.S. regulators have approved the first drug for bladder cancer that harnesses the body’s immune system. It is the first advance in decades against the most common type of bladder cancer, one which almost always kills patients within months.

Tecentriq won approval for treating patients with advanced urothelial cancer after chemotherapy stops helping them.

The drug, developed by the Roche Group’s Genentech unit, blocks a protein found on many tumor cells that deactivates key immune-system cells that kill cancer cells.